March 22, 2012 — We are pleased to announce that Paul Rhyne, Ph.D., is joining Tandem Labs as the Senior Technical Director for Biotechnology Services in our New Jersey laboratory. Dr. Rhyne joins Tandem Labs with over 15 years of immunoanalytical experience supporting pre-clinical and clinical drug development.
Since 2005, Dr. Rhyne has held various leadership positions at Bristol-Myers Squibb, most recently as Associate Director in the Bioanalytical Sciences and Biologics group in Lawrenceville, New Jersey. While at Bristol-Myers Squibb, Dr. Rhyne managed a group of scientists who developed and validated more than 200 clinical biomarker and pharmacokinetic assays used to support clinical studies.
Prior to Bristol-Myers Squibb, Dr. Rhyne held diverse roles in the industry, including R&D Manager at Upstate USA, Inc. where he developed a new product line on the Luminex platform consisting of over 60 cell-signaling multiplex assays. Dr. Rhyne also held scientific positions at Amplistar, Inc. and at St. Jude Children’s Research Hospital.
Dr. Rhyne has been the primary or contributing author on many industry publications and scientific presentations, covering such topics as electrochemiluminescence in bioanalysis, immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards, analysis of apoptotic cells using Beadlyte suspension arrays, and novel methods for the identification of cancer-associated antigens, among others.
Dr. Rhyne received his Ph.D. in cellular immunology from the University of Tennessee in Memphis and his M.S. in biology from the University of North Carolina in Charlotte. He is a member of the American Association of Pharmaceutical Scientists, the American Association of Immunologists, and the American Association for Clinical Chemistry.
Tandem Labs provides large- and small-molecule GLP-compliant bioanalytical services for drugs, metabolites, and biomarkers in a variety of matrices for discovery, pre-clinical, and clinical studies. As a contract lab focusing exclusively on bioanalytical services from four sites across the United States, we focus on building strong relationships with clients that allow us to develop programs that will meet even the most difficult challenges. Tandem Labs, Inc. is a wholly owned subsidiary of Laboratory Corporation of America® Holdings (NYSE: LH).